MorphoSys AG (MORG.DE)
104.90EUR
22 Jun 2018
€2.50 (+2.44%)
€102.40
€102.80
€105.20
€102.60
101,195
114,016
€105.20
€55.05
About
Overall
| Beta: | 0.78 |
| Market Cap(Mil.): | €2,171.58 |
| Shares Outstanding(Mil.): | 29.35 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| MORG.DE | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 82.81 | 32.74 |
| EPS (TTM): | -2.61 | -- | -- |
| ROI: | -19.28 | 2.00 | 14.38 |
| ROE: | -19.78 | 3.49 | 16.08 |
German stocks - Factors to watch on June 13
FRANKFURT/BERLIN, June 13 The following are some of the factors that may move German stocks on Wednesday:
German stocks - Factors to watch on May 17
BERLIN/FRANKFURT, May 17 The following are some of the factors that may move German stocks on Thursday:
BRIEF-Morphosys AG Reports Q1 Revenue Of 2.8 Million EUR
* Q1 REVENUE 2.8 MILLION EUR VERSUS 11.8 MILLION EUR YEAR AGO
BRIEF-Morphosys, Galapagos initiate IGUANA phase 2 clinical trial with Mor106 in Atopic Dermatitis patients
* DGAP-NEWS: MORPHOSYS AND GALAPAGOS ANNOUNCE INITIATION OF THE IGUANA PHASE 2 CLINICAL TRIAL WITH MOR106 IN ATOPIC DERMATITIS PATIENTS
BRIEF-MorphoSys Announces Approval Of Tremfya(R)In South Korea
* DGAP-NEWS: MORPHOSYS ANNOUNCES APPROVAL OF TREMFYA(R) (GUSELKUMAB) IN SOUTH KOREA
BRIEF-Morphosys Says NASDAQ IPO Leads To Total Gross Proceeds Of USD 239 Million
* DGAP-NEWS: MORPHOSYS ANNOUNCES CLOSING OF NASDAQ IPO THROUGH AN ADS OFFERING AND EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL ADSS, LEADING TO TOTAL GROSS PROCEEDS OF USD 239 MILLION
BRIEF-Morphosys Announces Pricing Of IPO Of American Depositary Shares On Nasdaq
* MORPHOSYS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES (ADSS) ON NASDAQ
BRIEF-Morphosys to increase capital to implement Offering Of 8.3 mln ADS
* DGAP-ADHOC: MORPHOSYS RESOLVES A CAPITAL INCREASE TO IMPLEMENT THE OFFERING OF 8,300,000 AMERICAN DEPOSITARY SHARES (ADS) IN THE UNITED STATES
BRIEF-Morphosys AG Sees U.S. IPO 8.3 Mln American Depositary Shares - SEC Filing
* MORPHOSYS AG SEES U.S. IPO 8.3 MLN AMERICAN DEPOSITARY SHARES - SEC FILING
BRIEF-Morphosys Says Tremfya Approved To Treat Psoriasis In Japan
* SAYS ANNOUNCES APPROVAL OF TREMFYA(R) (GUSELKUMAB) FOR THE TREATMENT OF MODERATE TO SEVERE FORMS OF PSORIASIS AND PSORIATIC ARTHRITIS IN JAPAN Source text for Eikon: Further company coverage:
Estimates